Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDC*lung01 in non-small-cell lung cancer
NL-OMON59873Phase 2Completed
- Sponsor
- PDC*line Pharma
- Start
- Nov 2021
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of PDC*lung01, sponsored by PDC*line Pharma. Started Nov 2021; status: completed.
02
Drugs
PDC*lung01
Beyond the preview
Go deeper on NL-OMON59873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59873.